Evidence map›Paper›PMID 16288286›Full record

ReviewOncogene2005

Class reunion: PTEN joins the nuclear crew.

Zenglin Lian, Antonio Di Cristofano

Abstract readReview
PubMed Publisher
In one paragraph

Review in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Review
  3. Nuclear phosphoinositide regulation of chromatin.Journal of cellular physiology · 2018
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN.The Journal of clinical endocrinology and metabolism · 2014
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Where is mTOR and what is it doing there?The Journal of cell biology · 2013
    Review
  16. Oncology letters · 2013
    Article
  17. Article
  18. Article
  19. PTEN in DNA damage repair.Cancer letters · 2012
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zenglin LianHuman Genetics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Antonio Di Cristofano
Fox Chase Cancer Center · US

Funding

PTEN and the Molecular Genetics of Endometrial CancerR01CA097097 · NCI · FOX CHASE CANCER CENTER · PI DI CRISTOFANO, ANTONIO · 2003 to 2012
$2.7M
NCI NIH HHS CA097097
6 · The paper itself

Abstract

Several recent reports have brought conclusive evidence that the tumor suppressor PTEN, once considered a strictly cytoplasmic protein, shuttles to the nuclear compartment, where it joins a variety of components of the same pathway it regulates in the cytoplasm, among which PI3K, PDK1 and AKT. In this review, we focus on the growing supporting evidence for an important physiological role of this nuclear pathway and on the role that alteration of this novel regulatory circuit may play during cell transformation.

Indexed as

Cell Transformation, Neoplastic3-Phosphoinositide-Dependent Protein KinasesCytoplasmHumansNuclear ProteinsPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktPTEN Phosphohydrolase3-Phosphoinositide-Dependent Protein KinasesNuclear ProteinsPDPK1 protein, humanPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, human

Identifiers

PMID16288286
OpenAlexW2006492820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.